Effect of canagliflozin on liver function tests in patients with type 2 diabetes

Diabetes and Metabolism

Volumn 42, Issue 1, 2016, Pages 25-32

  Leiter, L A ^a   Forst, T ^b   Polidori, D ^c   Balis, D A ^d   Xie, J ^d   Sha, S ^d  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b Profil Mainz   (Germany)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Body weight reduction; Canagliflozin; Glycaemic control; Liver function tests; Sodium glucose co transporter 2 inhibitor; Type 2 diabetes mellitus

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CANAGLIFLOZIN; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; DRUG EFFECT; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL (TOPIC); WEIGHT REDUCTION; AGED; ANALYSIS; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; ENZYMOLOGY; GLUCOSE BLOOD LEVEL; LIVER; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

AGED; BLOOD GLUCOSE; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIVER; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; WEIGHT LOSS;

EID: 84947998361     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2015.10.003     Document Type: Article

References (42)

1. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015, 38:140-149.
2. Rosenstock J., Aggarwal N., Polidori D., Zhao Y., Arbit D., Usiskin K., et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012, 35:1232-1238.
3. Stenlöf K., Cefalu W.T., Kim K.A., Alba M., Usiskin K., Tong C., et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013, 15:372-382.
4. Stenlöf K., Cefalu W.T., Kim K.A., Jodar E., Alba M., Edwards R., et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin 2014, 30:163-175.
5. Lavalle-González F.J., Januszewicz A., Davidson J., Tong C., Qiu R., Canovatchel W., et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013, 56:2582-2592.
6. Wilding J.P., Charpentier G., Hollander P., González-Gálvez G., Mathieu C., Vercruysse F., et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 2013, 67:1267-1282.
7. Forst T., Guthrie R., Goldenberg R., Yee J., Vijapurkar U., Meininger G., et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab 2014, 16:467-477.
8. Schernthaner G., Gross J.L., Rosenstock J., Guarisco M., Fu M., Yee J., et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial. Diabetes Care 2013, 36:2508-2515.
9. Bode B., Stenlöf K., Sullivan D., Fung A., Usiskin K. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract 2013, 41:72-84.
10. Cefalu W.T., Leiter L.A., Yoon K.-H., Arias P., Niskanen L., Xie J., et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013, 382:941-950.
11. Yale J.F., Bakris G., Cariou B., Yue D., David-Neto E., Xi L., et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013, 15:463-473.
12. Leiter L.A., Yoon K.-H., Arias P., Langslet G., Xie J., Balis D., et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care 2015, 38:355-364.
13. Yale J.F., Bakris G., Cariou B., Nieto J., David-Neto E., Yue D., et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab 2014, 16:1016-1027.
14. Neal B., Perkovic V., de Zeeuw D., Mahaffey K.W., Fulcher G., Ways K., et al. Efficacy and safety of canagliflozin, an inhibitor of sodium glucose co-transporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care 2015, 38:403-411.
15. Bode B., Stenlöf K., Harris S., Sullivan D., Fung A., Usiskin K., et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55 to 80 years with type 2 diabetes. Diabetes Obes Metab 2015, 17:294-303.
16. Devineni D., Morrow L., Hompesch M., Skee D., Vandebosch A., Murphy J., et al. Canagliflozin improves glycemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012, 14:539-545.
17. Sha S., Devineni D., Ghosh A., Polidori D., Chien S., Wexler D., et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011, 13:669-672.
18. Polidori D., Sha S., Ghosh A., Plum-Mörschel L., Heise T., Rothenberg P. Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013, 98:E867-E871.
19. Del Prato S. Role of glucotoxicity and lipotoxicity in the pathophysiology of type 2 diabetes mellitus and emerging treatment strategies. Diabet Med 2009, 26:1185-1192.
20. US Department of Health and Human Services, US Food and Drug Administration Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry drug-induced liver injury: premarketing clinical evaluation 2009, http://www.fda.gov/downloads/Drugs/Guidances/UCM174090.pdf.
21. European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP) European public assessment report (EPAR) for Jardiance (empagliflozin) 2014, EMEA/H/C/002677/0000. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002677/WC500168594.pdf.
22. Food and Drug Administration FDA Briefing Document. NDA 202293 Dapagliflozin tablets, 5 and 10 mg. Endocrinologic and Metabolic Drugs Advisory Committee Meeting 2011, http://www.fda.gov/downloads/AdvisoryCommittee/UCM262994.pdf.
23. Harris E.H. Elevated liver function tests in type 2 diabetes. Clin Diabetes 2005, 23:115-119.
24. Liang Y., Arakawa K., Ueta K., Matsushita Y., Kuriyama C., Martin T., et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One 2012, 7:e30555.
25. Tahara A., Kurosaki E., Yokono M., Yamajuku D., Kihara R., Hayashizaki Y., et al. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats. J Pharm Pharmacol 2014, 66:975-987.
26. Gasteyger C., Larsen T.M., Vercruysse F., Astrup A. Effect of a dietary-induced weight loss on liver enzymes in obese subjects. Am J Clin Nutr 2008, 87:1141-1147.
27. Promrat K., Lutchman G., Uwaifo G.I., Freedman R.J., Soza A., Heller T., et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004, 39:188-196.
28. Tarantino G., Saldalamacchia G., Conca P., Arena A. Non-alcoholic fatty liver disease: further expression of the metabolic syndrome. J Gastroenterol Hepatol 2007, 22:293-303.
29. Richard J., Lingvay I. Hepatic steatosis and type 2 diabetes: current and future treatment considerations. Expert Rev Cardiovasc Ther 2011, 9:321-328.
30. Ueno T., Sugawara H., Sujaku K., Hashimoto O., Tsuji R., Tamaki S., et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997, 27:103-107.
31. Vilar-Gomez E., Martinez-Perez Y., Calzadilla-Bertot L., Torres-Gonzalez A., Gra-Oramas B., Gonzalez-Fabian L., et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015, 149:367-378.
32. Eguchi Y., Kitajima Y., Hyogo H., Takahashi H., Kojima M., Ono M., et al. Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol Res 2015, 45:269-278.
33. Razavizade M., Jamali R., Arj A., Matini S.M., Moraveji A., Taherkhani E. The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic Fatty liver disease: a randomized double blinded clinical trial. Hepat Mon 2013, 13:e9270.
34. Belfort R., Harrison S.A., Brown K., Darland C., Finch J., Hardies J., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006, 355:2297-2307.
35. Mazza A., Fruci B., Garinis G.A., Giuliano S., Malaguarnera R., Belfiore A. The role of metformin in the management of NAFLD. Exp Diabetes Res 2012, 2012:716404.
36. Loomba R., Lutchman G., Kleiner D.E., Ricks M., Feld J.J., Borg B.B., et al. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2009, 29:172-182.
37. Shields W.W., Thompson K.E., Grice G.A., Harrison S.A., Coyle W.J. The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial. Therap Adv Gastroenterol 2009, 2:157-163.
38. Krakoff J., Clark J.M., Crandall J.P., Wilson C., Molitch M.E., Brancati F.L., et al. Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program. Obesity (Silver Spring) 2010, 18:1762-1767.
39. Tiikkainen M., Hakkinen A.M., Korsheninnikova E., Nyman T., Makimattila S., Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004, 53:2169-2176.
40. Tahara A., Kurosaki E., Yokono M., Yamajuku D., Kihara R., Hayashizaki Y., et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol 2013, 715:246-255.
41. Suzuki M., Takeda M., Kito A., Fukazawa M., Yata T., Yamamoto M., et al. Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models. Nutr Diabetes 2014, 4:e125.
42. Usiskin K., Kline I., Fung A., Mayer C., Meininger G. Safety and tolerability of canagliflozin in patients with type 2 diabetes: pooled analysis of phase 3 study results. Postgrad Med 2014, 126:16-34.